1. Home
  2. IMXI vs CBIO Comparison

IMXI vs CBIO Comparison

Compare IMXI & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMXI
  • CBIO
  • Stock Information
  • Founded
  • IMXI 1994
  • CBIO 2003
  • Country
  • IMXI United States
  • CBIO United States
  • Employees
  • IMXI N/A
  • CBIO N/A
  • Industry
  • IMXI Retail: Computer Software & Peripheral Equipment
  • CBIO
  • Sector
  • IMXI Technology
  • CBIO
  • Exchange
  • IMXI Nasdaq
  • CBIO Nasdaq
  • Market Cap
  • IMXI 302.5M
  • CBIO 308.0M
  • IPO Year
  • IMXI N/A
  • CBIO N/A
  • Fundamental
  • Price
  • IMXI $10.30
  • CBIO $12.96
  • Analyst Decision
  • IMXI Buy
  • CBIO Strong Buy
  • Analyst Count
  • IMXI 7
  • CBIO 2
  • Target Price
  • IMXI $19.60
  • CBIO $25.00
  • AVG Volume (30 Days)
  • IMXI 318.6K
  • CBIO 86.1K
  • Earning Date
  • IMXI 08-06-2025
  • CBIO 08-23-2025
  • Dividend Yield
  • IMXI N/A
  • CBIO N/A
  • EPS Growth
  • IMXI 1.60
  • CBIO N/A
  • EPS
  • IMXI 1.70
  • CBIO N/A
  • Revenue
  • IMXI $652,547,000.00
  • CBIO N/A
  • Revenue This Year
  • IMXI N/A
  • CBIO N/A
  • Revenue Next Year
  • IMXI $3.03
  • CBIO N/A
  • P/E Ratio
  • IMXI $6.02
  • CBIO N/A
  • Revenue Growth
  • IMXI N/A
  • CBIO N/A
  • 52 Week Low
  • IMXI $9.76
  • CBIO $11.06
  • 52 Week High
  • IMXI $22.38
  • CBIO $21.40
  • Technical
  • Relative Strength Index (RSI)
  • IMXI 45.01
  • CBIO N/A
  • Support Level
  • IMXI $10.22
  • CBIO N/A
  • Resistance Level
  • IMXI $10.87
  • CBIO N/A
  • Average True Range (ATR)
  • IMXI 0.34
  • CBIO 0.00
  • MACD
  • IMXI 0.05
  • CBIO 0.00
  • Stochastic Oscillator
  • IMXI 48.65
  • CBIO 0.00

About IMXI International Money Express Inc.

International Money Express Inc is a processor of money transfer services in the USA to the Latin America and the Caribbean (LAC) corridor. The company offers wire transfer, money order, Foreign exchange, and cash checking services, while the majority of the revenue is derived from wire transfer and money order fees. The firm's business is organized around one reportable segment that provides money remittance services between the U.S. and Canada to Mexico, Guatemala, and other countries in Latin America, Africa, and Asia.

About CBIO Crescent Biopharma Inc. Common Stock

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

Share on Social Networks: